Larry Norton
Oncology · 2000–2020
A researcher in the Science corpus: 26 papers; trusts 5 researchers and is trusted by 2 researchers here, as inferred from the citation graph.
Subfields
- Oncology — 173 citations into it; #1,175 of 1,698 by trust here, #132 by citations
- Molecular Biology — 104 citations into it
- Immunology — 32 citations into it
Whom Larry Norton trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- J. Massagué (in Oncology)
- T. Kishimoto (in Oncology)
- G. Gupta (in Oncology)
- J. Pollard (in Immunology)
- J. Joyce (in Oncology)
Who trusts Larry Norton
- R. Weinberg (in Oncology)
- H. Horlings (in Cancer Research)
Papers from Larry Norton's perspective
Ordered by how strongly the researchers Larry Norton trusts endorse each paper. Same corpus, a different order for every researcher.
- A multigenic program mediating breast cancer metastasis to bone. (Cancer Cell)
- Involvement of chemokine receptors in breast cancer metastasis (Nature)
- Molecular portraits of human breast tumours (Nature)
- From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression (Proceedings of the National Academy of Sciences of the United States of America)
- Gene expression profiling predicts clinical outcome of breast cancer
- Repeated observation of breast tumor subtypes in independent gene expression data sets (Proceedings of the National Academy of Sciences of the United States of America)
- Microenvironmental regulation of metastasis (Nature Reviews. Cancer)
- New functions for the matrix metalloproteinases in cancer progression (Nature Reviews. Cancer)
- Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
- Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. (Journal of the National Cancer Institute)
Their papers
- Exogenous Expression of N-Cadherin in Breast Cancer Cells Induces Cell Migration, Invasion, and Metastasis (2000) — 948 citations
- Latent bone metastasis in breast cancer tied to Src-dependent survival signals (2009) — 677 citations
- Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer (2017) — 650 citations
- The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers (2018) — 851 citations
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) — 1,189 citations
- Cancer therapy shapes the fitness landscape of clonal hematopoiesis (2020) — 599 citations
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† (2018) — 1,021 citations
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (2018) — 913 citations
- 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). (2017) — 674 citations
- Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. (2015) — 628 citations
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) (2014) — 634 citations
- A CXCL1 paracrine network links cancer chemoresistance and metastasis (2012) — 1,057 citations
- Tumor entrained neutrophils inhibit seeding in the premetastatic lung (2011) — 757 citations
- Tumor self-seeding by circulating cancer cells (2009) — 1,320 citations
- American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. (2007) — 1,250 citations
- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. (2007) — 1,118 citations
- Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. (2005) — 1,077 citations
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. (2005) — 7,387 citations
- Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial (2004) — 670 citations
- A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. (2004) — 1,015 citations